Literature DB >> 12685522

The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.

J M Swanson1, M Lerner, T Wigal, K Steinhoff, L Greenhill, K Posner, J Freid, S Wigal.   

Abstract

Recently, new long-acting formulations of racemic methylphenidate (MPH: Ritalin LA, Metadate CD and Concerta) and amphetamine (AMP: Adderall XR) were developed and are now approved by the Food and Drug Administration (FDA). In addition, dexmethylphenidate (Focalin), the pharmacologically active d-threo enantiomer of MPH, also was approved by the FDA. In the initial phases of development, prototypes of these five new formulations were evaluated using the University of California, Irvine (UCI) Laboratory School Protocol (LSP), in which surrogate measures of efficacy are collected in highly controlled settings rather than clinical measures of effectiveness in the less-controlled, natural environments of home or school. The LSP studies were followed by large effectiveness and safety studies required for gaining FDA approval. These initial efficacy and side effect studies in the LSP provided missing information about the basic pharmacokinetic (PK) and pharmacodynamic (PD) properties of MPH and AMP and produced some new discoveries (i.e., acute tolerance) that were used to help design the final products. The final once-a-day formulations used different drug delivery systems to achieve long-acting efficacy (Ritalin LA, Metadate CD, Concerta, Adderall XR). All four drug delivery systems were based on two processes: first, a bolus delivery (BD) process to achieve rapid onset of efficacy (mg), and second, a controlled delivery (CD) process to achieve rates of delivery (mg/hr) or a delayed bolus (mg) to maintain efficacy. A theoretical approach was used to compare and contrast the new once-a day formulations of MPH by selecting total daily doses (mg/d) that would equate drug delivery by the first process (mg of the initial bolus) and the second process (mg/hr over specified time period). In addition to efficacy, applications of the LSP to measure common side effects related to eating and sleeping were described and discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12685522     DOI: 10.1177/070674370200601s10

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  16 in total

Review 1.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

2.  Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.

Authors:  Sharon B Wigal; Tim Wigal; Sabrina Schuck; Matthew Brams; David Williamson; Robert B Armstrong; H Lynn Starr
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-04-13       Impact factor: 2.576

3.  Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting.

Authors:  Manfred Döpfner; Wolff Dieter Gerber; Tobias Banaschewski; Dieter Breuer; Franz Joseph Freisleder; Gabi Gerber-von Müller; Michael Günter; Frank Hässler; Claudia Ose; Aribert Rothenberger; Klaus Schmeck; Judith Sinzig; Christina Stadler; Henrik Uebel; Gerd Lehmkuhl
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

4.  A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior.

Authors:  Panayotis K Thanos; Lisa S Robison; Jessica Steier; Yu Fen Hwang; Thomas Cooper; James M Swanson; David E Komatsu; Michael Hadjiargyrou; Nora D Volkow
Journal:  Pharmacol Biochem Behav       Date:  2015-01-29       Impact factor: 3.533

Review 5.  Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Authors:  Sharon B Wigal
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis.

Authors:  Edmund J S Sonuga-Barke; Pol Van Lier; James M Swanson; David Coghill; Sharon Wigal; Mieke Vandenberghe; Simon Hatch
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-06       Impact factor: 4.785

7.  Drug therapy of attention deficit hyperactivity disorder: current trends.

Authors:  Avinash De Sousa; Gurvinder Kalra
Journal:  Mens Sana Monogr       Date:  2012-01

8.  Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.

Authors:  Feng Liu; Haruka Minami; Raul R Silva
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

9.  Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study.

Authors:  Sharon B Wigal; Seth C Hopkins; Kenneth S Koblan; Ann Childress; Justine M Kent; Joyce Tsai; Jay Hsu; Antony Loebel; Robert Goldman
Journal:  J Atten Disord       Date:  2019-08-02       Impact factor: 3.256

10.  Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.

Authors:  Edmund J S Sonuga-Barke; James M Swanson; David Coghill; Heleen H DeCory; Simon J Hatch
Journal:  BMC Psychiatry       Date:  2004-09-30       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.